1. Allogeneic hematopoietic stem cell transplantation in Primary Cutaneous T Cell Lymphoma
- Author
-
Giovanna De Santis, Raffaella Cerretti, Massimiliano Postorino, Alessandro Lanti, Fabio Di Piazza, Alessandra Picardi, Daniela Nasso, Francesco Pisani, Enrico Scala, Maria Cantonetti, Eleonora Ceresoli, Gottardo De Angelis, Benedetta Mariotti, and Laura Cudillo
- Subjects
Male ,medicine.medical_treatment ,Graft vs Host Disease ,Hematopoietic stem cell transplantation ,Severity of Illness Index ,Gastroenterology ,Cohort Studies ,0302 clinical medicine ,hemic and lymphatic diseases ,Secondary Prevention ,Cutaneous T cell lymphoma ,Hematology ,Incidence ,Graft vs Tumor Effect ,Remission Induction ,Hematopoietic Stem Cell Transplantation ,General Medicine ,Middle Aged ,Lymphoma, T-Cell, Cutaneous ,Italy ,030220 oncology & carcinogenesis ,Cord blood ,Female ,Adult ,Risk ,medicine.medical_specialty ,Cancer Care Facilities ,Disease-Free Survival ,Donor lymphocyte infusion ,Young Adult ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,Transplantation, Homologous ,Survival analysis ,Aged ,Neoplasm Staging ,Retrospective Studies ,Chemotherapy ,business.industry ,Cutaneous T-cell lymphoma ,Allogeneic stem cell transplantation ,medicine.disease ,Survival Analysis ,Lymphoma ,business ,Settore MED/15 - Malattie del Sangue ,Follow-Up Studies ,030215 immunology - Abstract
In our retrospective study, 16 patients affected by advanced cutaneous T cell lymphoma (CTCL) underwent allogeneic hematopoietic stem cell transplantation (HSCT). Two patients (12.5%) were in complete remission (CR), nine (56.3%) in partial remission (PR), and five (31.2%) with active disease. The patients were transplanted from an HLA-identical (n = 7) from a mismatched (n = 1) or haploidentical (n = 1) sibling, from matched unrelated donor (n = 5), or from a single cord blood unit (n = 2). Conditioning regimen was standard myeloablative in 6 patients and at reduced intensity in 10. Seven patients died from non relapse mortality (NRM) and four patients relapsed or progressed, three of them achieved a second CR after donor lymphocyte infusion (DLI) or chemotherapy plus DLI. To date, with a median follow-up of 76 months (range 6-130), nine patients are alive, eight in CR, and one with active disease. Overall survival (OS) and disease-free survival (DFS) at 1 and 10 years are 61% (95% CI 40-91%) and 54% (95% CI 33-86%), 40% (95% CI 22-74%), and 34% (95% CI 16-68%), respectively. The time from diagnosis to transplant seems to influence negatively both OS (log-rank p
- Published
- 2018